Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT
MDVN: 106.81 (-2.19), JNJ: 99.53 (+1.13)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.40 (+0.03), NBS: 2.25 (-0.09), OSIR: 19.31 (+0.65), BCLI: 3.46 (-0.03), MDVN: 106.81 (-2.19), INO: 7.46 (+0.19), CYTX: 0.47 (+0.01), STEM: 0.52 (+0.01), JUNO: 52.05 (+1.72), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01), BLUE: 159.03 (+0.60), VRTX: 122.95 (+2.06), AMGN: 154.10 (+2.79), KERX: 9.81 (+0.11), OMER: 17.33 (+0.29), KITE: 64.36 (+1.05), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75)
Why Chugai Pharmaceutica (CHGCY) Stock Is Down Today
at The Street - Mon Aug 18, 10:42AM CDT
Shares of Chugai Pharmaceutica (CHGCY) are down after the company denied reports that its parent Roche Holding (RHHBY) was said to be in talks to buy out the Japanese drugmaker.